Please Wait
Applying Filters...
menu
    • menu
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

    Stock Recap
    #PipelineProspector

    Menu

    Gammalin 20

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    24/02/2025 Sanofi
    France
    		 RHONE POULENC RORER PHARMACEUTICALS INC 8167 LINDANE 1989-08-15 Inactive II N/A
    24/02/2025 OLTA PHARMACEUTICALS CORP
    U.S.A
    		 OLTA PHARMACEUTICALS CORP 22259 LINDANE, USP 2009-01-08 Inactive II N/A